Table 4.
Socio-demographic and clinical characteristics of the samples of studies dealing with the addition of aripiprazole to lower prolactin.
| Reference | Country | Ethnicity | Age (years) Mean (SD) | Duration of illness (years) Mean (SD) | Duration of treatment with PRL-elevating antipsychotic | Substance use | Symptoms (baseline visit) |
|---|---|---|---|---|---|---|---|
| Kelly et al., 2018 | USA | 66% african american 33% white | 37.8 (8.9) | NR† | >2 months | Substance abuse was an exclusion criterion | Clinical stability (psychiatrist consideration) was an inclusion criterion BPRS: 35.4 (10.0) CGI-S: 3.8 (0.9) |
| Fujioi et al., 2017 | Japan | NR | 41.3 (8.0) | 15.2 (8.3) | >2 months | NR | BPRS: 44.1 (12.5) CGI-S: 4.0 (0.9) |
| Yoon et al., 2016 | Korea | NR | 35.8 (7.1) | 11.1 (7.3) | >1 month | Substance abuse or dependence was an exclusion criterion | Clinically stable over 2 months (no changes in CGI-S) |
| Qiaio et al., 2016 | China | NR | 34.1 (7.0) | 14.3 (20.9) | 1 month | Substance dependence was an exclusion criterion | PANSS total between 60 and 120 (inclusion criterion) PANSS total: 66.8 (14.2) |
| Chen et al., 2015 | China | NR | 34.4 (8.8) | 10.38 (7.0) | >6 weeks 9.2 (3.3) weeks |
Substance use was an exclusion criterion | Clinical stability (PANSS<70) was an inclusion criterion |
| Zhao et al., 2015 | China | NR | 28.9 (7.8) | 4.2 (4.2) months | >2 months | Substance use (including alcohol consumption) was an exclusion criterion | Stable psychiatric condition was an inclusion criterion PANSS total: 57.5 (13.5) |
| Ziadi Trives et al., 2013 | Spain | 100% white | 42.0 (11.4) | NR | >6 months | Substance use was an exclusion criterion | Clinical stability (no changes in treatment or ER visits in the previous 6 months) was an inclusion criterion CGI-S: 3.7 (1.3) |
| Van Kooten et al., 2011 | Netherlands | 83.3% white 16.6% asian |
47.6 (13.6) | 21.3 (12.2) | >12 months 43.2 (36) months |
NR | NR |
| Yasui-Furukori et al., 2010 | Japan | 44.5 (9.5) | 18.9 (13.4) | >3 months | NR | PANSS total: 72.9 (25.0) PANSS positive: 11.9 (3.5) PANSS negative: 19.6 (5.2) |
|
| Chen et al., 2010 | China (Taiwan) | NR | 37.4 (9.0) | 12.6 (9.1) | >1 month 9.3 (10.4) |
NR | PANSS total: 90.2 (57.2) |
| Chen et al., 2009 | China | NR | NR | NR | NR | NR | NR |
| Shim et al., 2007 | Korea | NR | 38.2 (5.3) | 15.3 (6.1) | >3 months | Substance use was an exclusion criterion | Clinical stability was an inclusion criterion BPRS: 45–5 (12.3) CGI-S: 4.2 (0.9) |
Abbreviations: SD= Standard deviation; NR= Not reported; CGI-S= Clinical Global Impression-Severity scale; PANSS= Positive and Negative Syndrome Scale; BPRS= Brief Psychiatric Rating Scale; ER= Emergency room.